Story
RegenLab Files for Nasdaq IPO With Ticker RGNA After Sales Jump 21%
Summary
Regenerative medicine firm RegenLab USA has filed a Form S-1 for an initial public offering on the Nasdaq, citing a 21% increase in first-half revenue to $29.3 million and a return to profitability.
Regenerative medicine developer RegenLab USA, Inc. has filed plans for an initial public offering on the Nasdaq Stock Market, according to a Form S-1 registration statement filed with the U.S. Securities and Exchange Commission. The company, which specializes in point-of-care cell processing devices, intends to list under the ticker symbol RGNA.
IPO Details
The Jersey City-based company has named StoneX Financial Inc. as the sole book-running manager for the proposed offering. The filing states that existing executive officers and directors have agreed to a customary 180-day lock-up period, restricting them from selling shares following the IPO pricing.
According to the registration statement, Chairman and CEO Antonino Turzi currently holds 98.64% of the company's voting power.
Financial Performance
RegenLab's filing revealed accelerating revenue growth and a recent return to profitability. For the six months ended June 30, 2026, the company reported:
Ad- Net product sales of $29.32 million, a 21% increase year-over-year.
- Operating income of $2.10 million, reversing a loss of $0.77 million from the prior-year period.
- Net income of $71,000, compared to a net loss of $32,000 in the first half of 2025.
For the full year of 2025, the company generated $49.17 million in revenue but posted a net loss of $1.24 million, which the filing attributed to increased research and development spending. Its two main product lines, RegenKit PRP and Cellular Matrix, accounted for over 90% of product sales in 2025.
Business and Strategy
RegenLab plans to use the net proceeds from the IPO to expand its direct sales and marketing teams, upgrade manufacturing equipment at its facilities in New Jersey, France, and Switzerland, and fund ongoing clinical trials. The company is currently advancing a Premarket Approval (PMA) submission with the FDA for its Cellular Matrix device for treating knee osteoarthritis.
The company supports its commercial distribution through strategic partnerships, including with Stryker Corp. for U.S. sports medicine and Smith+Nephew in Spain. Recent regulatory milestones include a May 2026 FDA 510(k) clearance for its RegenBMC bone marrow concentrate system.
Read next
More on Stocks
Bovespa Index Slips 0.27% as Basic Materials, Consumer Stocks Weigh
Brazil's benchmark Bovespa stock index ended Friday's session lower, weighed down by losses in the basic materials and consumption sectors. The decline occurred despite more individual stocks advancing than declining on the exchange.
Bipartisan Bill Seeks to Ban Chinese Optical Transceivers from US Government AI Systems
A group of U.S. lawmakers has introduced legislation to prohibit the federal government from using Chinese-made optical transceivers in sensitive systems, citing national security risks to AI and cloud infrastructure.
Circle CFO Jeremy Fox-Geen to Step Down; Co-Founder Exits Board
Circle Internet Group, the issuer of the USDC stablecoin, announced that Chief Financial Officer Jeremy Fox-Geen will step down. The leadership change also includes the departure of co-founder Sean Neville from the company's board.
Oura IPO Sees Demand Outstrip Supply by Four Times, Report Says
The health and fitness technology company's initial public offering is attracting significant investor interest, with orders reportedly reaching four times the shares available as it seeks to raise up to $2.2 billion.